Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 6, Issue 8 (2017)

Role of interleukin-17 in the disease course of different phenotypes of chronic obstructive pulmonary disease

Author(s):
Svitlana Bychkova
Abstract:

Work purpose - to study of immunologic features of the disease course of different COPD phenotypes – with chronic bronchitis and emphysema, and role of interleukin-17 in the pathogenesis of COPD. 87 male patients were involved in the examination, informed consents of all of them were obtained. Average age of patients was 53,9±4,5 years. Control group consisted of 36 persons, randomized by age and sex without any signs of COPD. Patients with chronic obstructive pulmonary disease with chronic bronchitis phenotype were observed to have signs of metabolic syndrome, lipid metabolism disorders and insulin resistance, unlike patients with emphysema phenotype. Patients of both clinical phenotypes have an equal severity of airway obstruction, exacerbation frequency and systemic arterial hypertension as a concomitant disease. Patients with COPD with phenotype of chronic bronchitis and frequent exacerbations have Th17 response predomination with significant elevation of IL-17, TGF-β, IL-6 concentrations in serum and high concentration of soluble adhesion molecules along with high expression of receptors to adhesion molecules on activated lymphocytes of peripheral blood. Patients with COPD emphysema phenotype with frequent exacerbations in immune system have Th1 response predomination with significantly higher concentrations of IFN-γ and lower levels of IL-4 and IL-10, along with high level of activated lymphocytes with CD25+ phenotype and low with CD30+ phenotype. In both groups of patients with chronic obstructive pulmonary disease a high serum level of proinflammatory cytokines (TNF-α, IL-1β and IL-8) was observed.
Pages: 264-267  |  601 Views  5 Downloads
How to cite this article:
Svitlana Bychkova. Role of interleukin-17 in the disease course of different phenotypes of chronic obstructive pulmonary disease. Pharma Innovation 2017;6(8):264-267.
The Pharma Innovation Journal